These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 37688519)
21. Advances in the diagnosis and treatment of sickle cell disease. Brandow AM; Liem RI J Hematol Oncol; 2022 Mar; 15(1):20. PubMed ID: 35241123 [TBL] [Abstract][Full Text] [Related]
22. Epidemiology and treatment of relative anemia in children with sickle cell disease in sub-Saharan Africa. Bello-Manga H; DeBaun MR; Kassim AA Expert Rev Hematol; 2016 Nov; 9(11):1031-1042. PubMed ID: 27677923 [TBL] [Abstract][Full Text] [Related]
23. Management of Sickle Cell Disease in Children. Noronha SA; Sadreameli SC; Strouse JJ South Med J; 2016 Sep; 109(9):495-502. PubMed ID: 27598348 [TBL] [Abstract][Full Text] [Related]
24. Red cell exchange transfusions increase cerebral capillary transit times and may alter oxygen extraction in sickle cell disease. DeBeer T; Jordan LC; Waddle S; Lee C; Patel NJ; Garza M; Davis T; Pruthi S; Jones S; Donahue MJ NMR Biomed; 2023 May; 36(5):e4889. PubMed ID: 36468659 [TBL] [Abstract][Full Text] [Related]
25. Gastrointestinal and hepatic complications of sickle cell disease. Ebert EC; Nagar M; Hagspiel KD Clin Gastroenterol Hepatol; 2010 Jun; 8(6):483-9; quiz e70. PubMed ID: 20215064 [TBL] [Abstract][Full Text] [Related]
26. Sickle cell disease: current treatment and emerging therapies. Neumayr LD; Hoppe CC; Brown C Am J Manag Care; 2019 Nov; 25(18 Suppl):S335-S343. PubMed ID: 31809007 [TBL] [Abstract][Full Text] [Related]
27. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. DeBaun MR; Jordan LC; King AA; Schatz J; Vichinsky E; Fox CK; McKinstry RC; Telfer P; Kraut MA; Daraz L; Kirkham FJ; Murad MH Blood Adv; 2020 Apr; 4(8):1554-1588. PubMed ID: 32298430 [TBL] [Abstract][Full Text] [Related]
28. The Development of Neuroimaging Biomarkers for Cognitive Decline in Sickle Cell Disease. Ramos K; Guilliams KP; Fields ME Hematol Oncol Clin North Am; 2022 Dec; 36(6):1167-1186. PubMed ID: 36400537 [TBL] [Abstract][Full Text] [Related]
29. Sickle cell disease: a review for the internist. Pinto VM; Balocco M; Quintino S; Forni GL Intern Emerg Med; 2019 Oct; 14(7):1051-1064. PubMed ID: 31385153 [TBL] [Abstract][Full Text] [Related]
30. Primary and Secondary Stroke Prevention in Children With Sickle Cell Disease. Mack AK; Thompson AA J Pediatr Health Care; 2017; 31(2):145-154. PubMed ID: 27423528 [TBL] [Abstract][Full Text] [Related]
32. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Hulbert ML; McKinstry RC; Lacey JL; Moran CJ; Panepinto JA; Thompson AA; Sarnaik SA; Woods GM; Casella JF; Inusa B; Howard J; Kirkham FJ; Anie KA; Mullin JE; Ichord R; Noetzel M; Yan Y; Rodeghier M; Debaun MR Blood; 2011 Jan; 117(3):772-9. PubMed ID: 20940417 [TBL] [Abstract][Full Text] [Related]
33. Neuroimaging in Sickle Cell Disease: A Review. Mallon D; Doig D; Dixon L; Gontsarova A; Jan W; Tona F J Neuroimaging; 2020 Nov; 30(6):725-735. PubMed ID: 33463866 [TBL] [Abstract][Full Text] [Related]
34. Voxelotor for the treatment of sickle cell disease. Vissa M; Vichinsky E Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029 [No Abstract] [Full Text] [Related]
35. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019. Tang AY; Zhou M; Maillis AN; Lai KW; Lane PA; Snyder AB Pediatr Blood Cancer; 2023 Mar; 70(3):e30152. PubMed ID: 36579749 [TBL] [Abstract][Full Text] [Related]
36. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Ware RE; Davis BR; Schultz WH; Brown RC; Aygun B; Sarnaik S; Odame I; Fuh B; George A; Owen W; Luchtman-Jones L; Rogers ZR; Hilliard L; Gauger C; Piccone C; Lee MT; Kwiatkowski JL; Jackson S; Miller ST; Roberts C; Heeney MM; Kalfa TA; Nelson S; Imran H; Nottage K; Alvarez O; Rhodes M; Thompson AA; Rothman JA; Helton KJ; Roberts D; Coleman J; Bonner MJ; Kutlar A; Patel N; Wood J; Piller L; Wei P; Luden J; Mortier NA; Stuber SE; Luban NLC; Cohen AR; Pressel S; Adams RJ Lancet; 2016 Feb; 387(10019):661-670. PubMed ID: 26670617 [TBL] [Abstract][Full Text] [Related]
37. The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation. Cherry MG; Greenhalgh J; Osipenko L; Venkatachalam M; Boland A; Dundar Y; Marsh K; Dickson R; Rees DC Health Technol Assess; 2012; 16(43):1-129. PubMed ID: 23140544 [TBL] [Abstract][Full Text] [Related]
38. Vasculopathy in Sickle Cell Disease: From Red Blood Cell Sickling to Vascular Dysfunction. Nader E; Conran N; Romana M; Connes P Compr Physiol; 2021 Apr; 11(2):1785-1803. PubMed ID: 33792905 [TBL] [Abstract][Full Text] [Related]